Zepbound降价后销量翻三倍,礼来Q3业绩超预期,并上调全年业绩指引

华尔街见闻
Oct 30, 2025

礼来第三季度每股收益7.02美元,营收达176亿美元,双双超出分析师预期,并将2025财年营收预期上调至630亿美元至635亿美元。三季度减肥药销售强劲,Mounjaro营收同比增长109%,Zepbound营收大幅增长184%。得益于减重药Zepbound和糖尿病治疗药物Mounjaro持续强劲的市场需求,礼来第三季度业绩全面超越市场预期并上调全年指引。礼来周四公布的财报显示,第三季度每股收益...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10